# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,844,192 B2 DATED : January 18, 2005

DATED : January 18, 2005 INVENTOR(S) : Orlando et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

#### Column 4,

Line 33, should read -- arginine to lysine substitutions within the amphiphatic  $\alpha$  --

Line 36, should read -- athic α helix (E4orf6 residues 239-255, SEQ ID NO:26) and --

Line 39, should read -- ID NO:27). (B) HeLa cells were infected with a recombinant --

Line 41, should read -- polymerase and then transfected with cDNA under control --

Line 59, should read -- immunoblotting with MAb 3 (Marton et al. (1990) J. Virol. --

# Column 5,

Line 63, should read -- tation of the α helical peptides is the same as seen in FIG. 1B --

#### Column 6,

Line 2, should read --  $R_{240.244.251}A$ , 62%; (G)  $R_{241}E$ , 0.8%. --

Line 22, should read -- FIG. 8 shows the key features of the amphipathic  $\alpha$  helix --

Line 31, should read -- region corresponding to amphipathic α helix. The arginine --

#### Column 7,

Line 1, should read -- cytotoxicity is cell type-specific. The cells indi---

Line 8, should read -- presence of 600 µg/ml G418. After 21 days, the number of --

# Column 38,

Line 52, should read -- substitution mutation and an arginine 251 to glutamic acid --

### Column 40,

Line 15, should read -- ing of glutamic acid, aspartic acid, serine, threonine, alanine --

Signed and Sealed this

Page 1 of 1

Twelfth Day of July, 2005

JON W. DUDAS
Director of the United States Patent and Trademark Office